ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Gilead Sciences strikes partnerships with Scholar Rock and Agenus

by Ryan Cross
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

 

Gilead Sciences formed two partnerships in the final weeks of 2018. The firm is collaborating with Scholar Rock to develop antibodies that inhibit transforming growth factor (TGF) to treat fibrotic diseases. Scholar Rock will earn $80 million up front and up to $1.45 billion more depending on the success of three TGF programs. Separately, Gilead is paying Agenus $150 million to develop up to five cancer immunotherapies, including two bispecific antibodies. Agenus could earn up to $1.7 billion in milestones.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment